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E-mail address: djﬁnk@umich.edu (D.J. Fink).Pain is a common and debilitating accompaniment of neuropathy that occurs as a complication of diabe-
tes. In the current study, we examined the effect of continuous release of gamma amino butyric acid
(GABA), achieved by gene transfer of glutamic acid decarboxylase (GAD67) to dorsal root ganglia
(DRG) in vivo using a non-replicating herpes simplex virus (HSV)-based vector (vG) in a rat model of pain-
ful diabetic neuropathy (PDN). Subcutaneous inoculation of vG reduced mechanical hyperalgesia, ther-
mal hyperalgesia and cold allodynia in rats with PDN. Continuous release of GABA from vector
transduced cells in vivo prevented the increase in the voltage-gated sodium channel isoform 1.7
(NaV1.7) protein that is characteristic of PDN. In vitro, infection of primary DRG neurons with vG pre-
vented the increase in NaV1.7 resulting from exposure to hyperglycemia. The effect of vector-mediated
GABA on NaV1.7 levels in vitro was blocked by phaclofen but not by bicuculline, a GABAB receptor effect
that was blocked by pertussis toxin-(PTX) interference with Ga(i/o) function. Taken in conjunction with
our previous observation that continuous activation of delta opioid receptors by vector-mediated release
of enkephalin also prevents the increase in NaV1.7 in DRG exposed to hyperglycemia in vitro or in vivo, the
observations in this report suggest a novel common mechanism through which activation of G protein
coupled receptors (GPCR) in DRG neurons regulate the phenotype of the primary afferent.
 2011 Published by Elsevier Ltd. on behalf of European Federation of International Association for the
Study of Pain Chapters.1. Introduction
Neuropathy is a major complication of diabetes mellitus, and a
common cause of neuropathic pain (Tavakoli et al., 2008). Like
other forms of chronic neuropathic pain, painful diabetic neuropa-
thy (PDN) is difﬁcult to treat (Finnerup et al., 2010). In an attempt
to directly target delivery of analgesic peptides to nociceptive
pathways (Mata et al., 2008) we have developed a series of non-
replicating herpes simplex virus (HSV)-based vectors that efﬁ-
ciently target gene delivery to dorsal root ganglia (DRG) from skin
inoculation (Glorioso and Fink, 2004; Wolfe et al., 1999). In
previous studies we have demonstrated the efﬁcacy of HSV vectors
designed to release enkephalin, endomorphin-2 or gamma
aminobutyric acid (GABA) in models of inﬂammatory pain, central
neuropathic pain, and pain caused by cancer (Goss et al., 2002,
2001; Hao et al., 2003, 2009; Liu et al., 2004; Wolfe et al., 2007).
The ﬁrst of these HSV-based vectors, a non-replicating HSV vector
expressing preproenkephalin is currently in clinical trial in patients
with intractable pain from cancer (Wolfe et al., 2009).on behalf of European Federation o
Center Drive, Ann Arbor, MI
763 5059.The role of spinal GABA in neuropathic pain syndromes is
uncertain. Several recent studies have suggested that in models
of chronic pain induced by inﬂammation or peripheral nerve in-
jury, a reduction in the expression of the potassium chloride
cotransporter 2 (KCC2) in neurons of the superﬁcial spinal dorsal
horn may induce a shift in the effect of GABA on the GABAA recep-
tor from inhibitory to excitatory (Coull et al., 2003; Zhang et al.,
2008) and thus contribute to the neuropathic pain phenotype
(Mantyh and Hunt, 2004; Zhang et al., 2008). Despite these obser-
vations, we previously found that inoculation of an HSV vector
encoding glutamic acid decarboxylase (GAD) that results in release
of GABA in the dorsal horn is effective in reducing pain-related
behaviors in the spinal nerve ligation model of neuropathic pain
(Hao et al., 2005).
The rodent model of PDN in rats with streptozotocin (STZ)-
induced diabetes is characterized by increased amounts of the
voltage-gated sodium channel a subunit isoform 1.7 (NaV1.7) in
DRG (Hong et al., 2004; Hong and Wiley, 2006), an increase that
occurs as a result of a post-transcriptional process mediated by
protein kinase C (PKC) (Chattopadhyay et al., 2008). We previously
observed that HSV-mediated expression of enkephalin in DRG of
diabetic animals results in a reduction in the amount of NaV1.7
protein in DRG neurons in vivo, coincident with a reduction in
pain-related behaviors (Chattopadhyay et al., 2008). Because off International Association for the Study of Pain Chapters.
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utor to the neuropathic pain phenotype (Dib-Hajj et al., 2007;
Drenth and Waxman, 2007), the reduction of NaV1.7 produced by
delta opioid receptor (DOR) activation represents an additional ef-
fect, beyond the well-recognized effects of enkephalin as an inhib-
itory neurotransmitter, through which enkephalin might act to
reduce neuropathic pain in PDN.
The current study was undertaken to answer two questions: (1)
would HSV-mediated release of GABA from primary afferents re-
duce neuropathic pain in rats with PDN; and (2) would HSV-med-
iated release of GABA reduce NaV1.7 protein levels in the DRG of
rats with PDN?2. Materials and methods
2.1. Vector construct
The non-replicating HSV vector vG is defective in expression of
the HSV immediate early (IE) genes ICP4, ICP22, ICP2 and ICP47
and contains the human GAD67 gene under the control of the hu-
man cytomegalovirus immediate early promoter (HCMV IEp) in the
UL41 locus. Construction and characterization of this vector has
been previously described (referred to as QHGAD67 in (Liu et al.,
2004)). Control vector vZ is identical to vG except that it contains
the E. coli lacZ reporter gene under the control of the HCMV IEp
in the HSV tk locus (referred to as Q0ZHG in (Liu et al., 2004)).
2.2. Animal studies
All the experiments were conducted on young adult male Spra-
gue Dawley rats weighing 200–250 g (Charles River; Portage, MI,
USA) at the start of the experiment, and were in compliance with
approved institutional animal care and use protocols and in confor-
mance with the ethical standards of the AAALAC and IASP. Rats
were rendered diabetic by injection of streptozotocin (STZ;
50 mg/kg, ip; Sigma, St Louis, MO, USA). The average blood glucose
levels of animals in the study were 522 ± 12/9 mg/dl in the diabetic
group and 140 ± 9 mg/dl in the control group. At 2 weeks after
injection of STZ, groups of 10 rats were injected with 30 ll contain-
ing 1  107 plaque forming units (pfu) of either of vG, vZ, or a sim-
ilar volume of vehicle alone subcutaneously into the plantar
surface of both hind feet. Ten animals that did not receive STZ
served as normal controls. All analyses were carried out by an ob-
server blinded to the treatment group 4 weeks after vector inocu-
lation (at 6 weeks of diabetes). A separate group of rats were
injected in a similar fashion with vG and sacriﬁced by perfusion
7 days later for the studies of transgene expression in vivo.
2.3. Behavioral studies
2.3.1. Thermal hyperalgesia
The latency to hind-paw withdrawal from a thermal stimulus
was determined by exposing the plantar surface of the hind paw
to radiant heat using a modiﬁed Hargreaves thermal testing device
(Hargreaves et al., 1988) as described (Chattopadhyay et al., 2008).
Mechanical hyperalgesia. Mechanical nociceptive threshold was as-
sessed using an analgesimeter (Ugo Basile, Comerio, VA, Italy)
(Chattopadhyay et al., 2008; Randall and Sellito, 1957). Cold allo-
dynia. Cold allodynia was assessed by withdrawal from acetone
spray, as described (Chattopadhyay et al., 2008).
2.4. Adult DRG culture
DRGwere removed from adult female rats, treated with collage-
nase (0.25%, Sigma, St Louis, MO, USA) for 1 h at 37 C and thendissociated with 2.5% trypsin (Sigma) in 1 mmol/l ethylene-
diaminetetraacetic acid (EDTA; Sigma) for 30 min at 37 C before
being plated on laminin, poly-D-lysine-coated coverslips at 105
cells per well in a 24-well plate in 500 ll of deﬁned Neurobasal
medium containing B27, Glutamax I, Albumax II and penicillin/
streptomycin (Gibco-BRL, Carlsbad, CA, USA), supplemented with
100 ng/ml of 7.0S NGF per ml (Sigma, St. Louis, MO, USA). To model
hyperglycemic conditions, 20 mM glucose was added to medium
(45 mM total glucose) that did not contain B27.2.5. Embryonic DRG culture
DRG from 17-day rat embryos were cultured as previously de-
scribed (Chattopadhyay et al., 2008). At 17 days in vitro the med-
ium was changed to 45 mM glucose (20 mM glucose in addition
to the basal 25 mM glucose) with Glutamax I, Albumax II, penicil-
lin/streptomycin and NGF, but without B27. Control cells were ex-
posed to identical medium lacking B27 with a total of 25 mM
glucose.2.6. Reagents
Bicuculline, (EC50: 10–100 lM (Rho et al., 1996); Sigma, St.
Louis, MO); phaclofen, (EC50: 229–500 lM (Robinson et al., 1989;
Shibuya et al., 1992); Biomol, Plymouth Meeting, PA); baclofen,
(EC50: 2.8–10 lM (Ong et al., 1990; Robinson et al., 1989); Sigma,
St. Louis, MO); pertussis toxin (PTX; Tocris, Ellisville, MO); cholera
toxin (CTX; Sigma, St. Louis, MO).2.7. Western blot
Western blot was performed as previously described
(Chattopadhyay et al., 2008) using the primary antibodies against
NaV1.7 (1:400, Millipore, Bedford, MA); pPKCab (1:400 Cell Signal-
ing, Beverly, MA); GAD67 (1:500; Millipore); b-actin (1:2000;
Sigma) and secondary horseradish peroxidase-conjugated anti-
rabbit IgG or anti-mouse IgG (1:5000 Amersham, Piscataway, NJ)
visualized with ECL (Pierce, Rockford, IL). The intensity of each
band was determined by quantitative chemiluminescence using a
PC-based image analysis system (ChemiDoc XRS System, Bio-Rad
Laboratories) and normalized to the respective level of b-actin.
The speciﬁcity of the commercially obtained anti-NaV antibody
for NaV1.7 was conﬁrmed in primary neurons in culture using an
HSV vector expressing an shRNA speciﬁc for NaV1.7 to selectively
knock-down NaV1.7 expression (Supplementary Fig. 1).2.8. Immunocytochemistry
Immunocytochemistry was performed as previously described
(Chattopadhyay et al., 2008) using the primary antibodies anti-
GAD67 (1:1000; Chemicon, Temecula, CA, USA) or NaV1.7 (1:500;
Neuromab; UC Davis, CA) and GABABR (1:400; Santa Cruz Biotech-
nology, Santa Cruz, CA) and the secondary ﬂuorescent antibody,
Alexa Fluor 594 goat anti-rabbit IgG (1:1000, Molecular Probes, Eu-
gene, OR).2.9. Statistical analysis
The statistical signiﬁcance of the difference between groups
was determined by ANOVA (Systat 9) using Bonferroni’s correction
for the multiple post hoc analyses. All results are expressed as
mean ± SEM. All the tissue culture experiments were repeated
three times. The animal experiments, with 8–10 animals per group,
were repeated twice.
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3.1. HSV vector vG expresses GAD67 in DRG neurons in vitro and
in vivo
Primary DRG neurons transduced at a multiplicity of infection
(MOI) of 1 by vG showed a substantial increase in GAD67 expres-
sion compared to control or vZ-infected cells in vitro by Western
blot and immunocytochemistry (Supplementary Fig. 2). Following
subcutaneous inoculation into the hind foot, rats inoculated with
the vector vG showed increased GAD67 expression in lumbar
DRG by Western blot and immunocytochemistry (7 days after
vector inoculation; Supplementary Fig. 2). In previous studies
we have reported that infection of DRG with this non-replicating
vector results in constitutive release of GABA from primary affer-
ent terminals in the dorsal horn of spinal cord (Liu et al., 2006,
2004).
3.2. Continuous release of GABA reduces thermal hyperalgesia,
mechanical hyperalgesia and cold allodynia in diabetic animals
4 weeks after inoculation of the vector vG
Diabetic animals demonstrated thermal hyperalgesia mani-
fested by a decrease in withdrawal latency in response to noxious
thermal stimuli (Fig. 1a). Four weeks after inoculation of vG
(6 weeks after diabetes) there was a statistically signiﬁcant in-
crease in thermal latency in vG treated animals compared to dia-
betic and control vector vZ-inoculated diabetic animals (Fig. 1a).
Diabetic rats also developed mechanical hyperalgesia 6 weeks after
diabetes, and inoculation of vG signiﬁcantly increased hind-paw
withdrawal threshold compared to diabetic animals (Fig. 1b) mea-
sured 4 week after inoculation. Diabetic animals inoculated with
vZ showed no difference in mechanical threshold compared to dia-
betic animals (Fig. 1b). Diabetic rats also developed cold allodynia
6 weeks after diabetes, with the latency to withdraw from the colda
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Fig. 1. Vector mediated expression of GABA reverses pain-related behaviors in anim
Mechanical hyperalgesia (Randall Selitto test) threshold in grams. (c) Cold allodynia in
diabetic inoculated with vZ; all data presented as mean ± SEM, n = 6–8 per group. #P < 0stimulus signiﬁcantly decreased in diabetic compared to control
animals (Fig. 1c). Diabetic animals inoculated with vG showed a
normal latency to withdraw from this stimulus (Fig. 1c).3.3. Vector-mediated release of GABA prevents the increase in NaV1.7
and pPKCab in diabetic DRG in vivo
As reported previously (Chattopadhyay et al., 2008; Hong et al.,
2004) there was a signiﬁcant increase in NaV1.7 protein in diabetic
compared to control DRG 6 weeks after diabetes (Fig. 2a). Animals
inoculated with vG 2 weeks after induction of diabetes by STZ
showed a substantial and signiﬁcant reduction in the amount of
NaV1.7 in DRG at 4 weeks after vector inoculation compared to ani-
mals inoculated with vZ (Fig. 2b). Similarly, the amount of pPKCab
was increased signiﬁcantly in diabetic DRG compared to control,
but in animals inoculated with vG 2 weeks after induction of dia-
betes by STZ there was a substantial and signiﬁcant reduction in
the amount of pPKCab in DRG at 4 weeks after vector inoculation
(Fig. 3a and b).3.4. Modulation of NaV1.7 by glucose in adult DRG neurons in vitro
In order to study the relationship of the amount of NaV1.7 in
DRG neurons to hyperglycemia we compared the adult DRG cul-
ture with primary E17 DRG neurons in vitro. The adult neurons
constitutively express NaV1.7 similar to primary embryonic
DRG. After 18 h exposure to culture medium containing 45 mM
glucose there was a substantial increase in the amount of
NaV1.7 protein in the adult DRG (Fig. 4) that was similar to that
seen in embryonic DRG in culture; the subsequent experiments
were conducted using embryonic DRG neurons in order to min-
imize the number of animals that would need to be employed
for these studies.0
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als with PDN. (a) Thermal withdrawal latency (Hargreave’s test) in seconds. (b)
seconds. C – naïve control; D – diabetic; DvG – diabetic inoculated with vG; DvZ –
.0001 or P < 0.001 vs. untreated diabetic animals or DvZ.
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Fig. 2. vG mediated GABA expression attenuates the increase in NaV1.7 in DRG in vivo characteristic of PDN. Amount of NaV1.7 determined by Western blot, normalized to D
(a) or DvZ (b). C – control; D – diabetic; DvG – diabetic inoculated with vG; DvZ – diabetic inoculated with vZ; P < 0.001 or P < 0.01; n = 5 animals per group. Representative
Western blots showing one sample from each group are presented above each graph.
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Fig. 3. Inoculation of vG prevents phosphorylation of PKC in diabetic DRG in vivo. Amount of pPKCab determined by Western blot, normalized to D (a) or DvZ (b). P < 0.005;
n = 5 animals per group. C – Control; D – diabetic; DvG – diabetic inoculated with vG; DvZ – diabetic inoculated with vZ. Representative Western blots showing one sample
from each group are presented above each graph.
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Fig. 4. NaV1.7 levels are increased in adult DRG neurons in culture exposed to
hyperglycemic conditions. Adult DRG neurons in culture were exposed to medium
containing 45 mM glucose for 18 h, and the amount of NaV1.7 determined by
Western blot.
β-actin
C
no
rm
al
iz
ed
 v
al
ue
0
50
100
150a
G
∗
GvG
∗∗
  Nav1.7
Fig. 5. Transgene-mediated expression of GABA prevents the increase in NaV1.7 in pr
reduction in the amount of NaV1.7 in hyperglycemic neurons treated with vG as determin
blot, normalized to C. P < 0.005 or P < 0.01; C – control; G – hyperglycemia; GvG – hyp
from each group are presented above each graph.
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expression and phosphorylation of PKC in primary DRG neurons
in vitro exposed to hyperglycemia
Transfection of cells exposed to hyperglycemia with vG at an
MOI of 1 blocked the increase in NaV1.7 resulting from exposure
to glucose (Fig. 5a). There was a substantial increase in the amount
of pPKCab in the primary DRG neurons exposed to hyperglycemic
conditions. Transfection of cells exposed to hyperglycemia with vG
at an MOI of 1 blocked the increase in phosphorylation resulting
from exposure to hyperglycemic conditions in vitro (Fig. 5b).
3.6. The effect of vector-mediated release of GABA on NaV1.7 is
reversed by phaclofen but not by bicuculline
In order to assess the relative contribution of GABAA and GABAB
receptors in mediating the effects of vector-produced GABA, DRGb
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fection, exposed to 45 mM glucose along with either 50 lM of
bicuculline or 500 lM phaclofen. Addition of bicuculline had no
effect on the decrease in NaV1.7 resulting from transfection with
vG (Fig. 6a). In contrast, the effect of transfection with vG in
preventing the increase in NaV1.7 was completely blocked by the
addition of 500 lM phaclofen (Fig. 6b). This ﬁnding was conﬁrmed
by experiments using the GABABR agonist baclofen. Addition of
10 lM baclofen (Fig. 6c) to primary DRG neurons exposed to
hyperglycemia blocked the increase in NaV1.7 resulting from
hyperglycemia. Colocalization of GABABR and NaV1.7 in individual β-actin
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chemistry (Supplementary Fig. 3).
3.7. GABAB receptor-mediated regulation of voltage-gated sodium
channel NaV1.7 involves PKC in DRG neurons in vitro
We previously found that inhibition of PKC activation by addi-
tion of 10 lMmyristolated PKC inhibitor 20–28 blocks the increase
in NaV1.7 in primary DRG neurons exposed to hyperglycemia
(Chattopadhyay et al., 2008). To test whether the effect of GABA
receptor activation proceeds through PKC, cells were transfectedvG+Phac
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45 mM glucose along with either 50 lM of bicuculline or 500 lM
phaclofen. Addition of bicuculline to vG-transfected cells exposed
to hyperglycemic conditions resulted in no change in pPKCab,
while the addition of phaclofen to vG-transfected cells prevented
the vG effect of pPKCab (Fig. 7a and b). These results support that
the vector mediated effect through the GABABR involves a block in
phosphorylation of PKC downstream of GABABR activation.3.8. Continuous activation of the GABABR by vector in reduction of NaV
1.7 is mediated through activation of Ga(i/o) proteins
G proteins are the key signal transducing molecules for G-pro-
tein coupled receptors (GPCRs). Treatment of primary DRG neurons
exposed to hyperglycemia with PTX (250 ng/ml overnight) blocked
the effect of GABABR activation on the amount of NaV1.7, but treat-
ment with CTX (250 ng/ml overnight) did not result in any change
in amount of NaV 1.7 (Fig. 8a and b). These results indicate that the
effect of GABA on NaV1.7 levels is mediated through Gi/o proteins.4. Discussion
There are two important observations in this study: (1) spinal
release of GABA effected by transfection of DRG neurons in vivo
with a GAD expressing vector reduces pain-related behaviors in
rats with PDN; and (2) continuous exposure to GABA reverses
the increase in NaV1.7 in primary sensory afferents that is charac-
teristic of diabetic neuropathy through a GABABR mediated
pathway.4.1. HSV-mediated release of GABA reduces neuropathic pain-related
behaviors in rats with PDN
In previous reports we have demonstrated that subcutaneous
inoculation of non-replicating HSV-based vectors results in trans-
fection of DRG neurons in vivo (Chattopadhyay et al., 2003; Goss
et al., 2001), and that infection of DRG neurons with the HSV vector
expressing GAD67 results in constitutive release of GABA (Liu et al.,
2006, 2004). Transfection of DRG neurons in vivowith the HSV vec-
tor expressing GAD67 reduces pain-related behaviors in the lateral
hemisection model of central neuropathic pain (Liu et al., 2004)
and in the selective spinal nerve ligation model of peripheral
neuropathic pain (Hao et al., 2005). The results of the current studyextend these ﬁndings to a model of the clinically prevalent neuro-
pathic pain condition caused by diabetes.
Tonic spinal GABAergic inhibition plays an important role in the
modulation of basal pain sensation. Intrathecal bicuculline in nor-
mal animals produces hyperalgesia (Hwang and Yaksh, 1997), and
reductions in both GAD and GABA in dorsal horn have been re-
ported in models of pain created by peripheral nerve injury (Cas-
tro-Lopes et al., 1993; Eaton et al., 1998; Ibuki et al., 1997;
Moore et al., 2002). In addition to our studies with HSV mediated
gene transfer of GAD, direct injection of an adeno-associated
virus-based vector expressing GAD65 into DRG neurons reduces
pain related symptoms in animals with neuropathic pain (Lee
et al., 2007) and intrathecal administration of baclofen produces
an antinociceptive effect in acute pain (Dirig and Yaksh, 1995; Mal-
cangio and Bowery, 1995; Smith et al., 1994), in animal models of
pain following nerve injury (Castro-Lopes et al., 1995; Engle et al.,
2006; Smith et al., 1994; Yang, 2004) and in rats with PDN (Mal-
cangio and Tomlinson, 1998).
GABA acting through the GABAA receptor may also function as
an excitatory neurotransmitter as it does during development or
in conditions characterized by a reduction in the expression of
KCC2 (Coull et al., 2003; Zhang et al., 2008) including PDN (Jolivalt
et al., 2008). How might we reconcile the differences between the
evidence that GABA may function as an excitatory neurotransmit-
ter in PDN with the current studies demonstrating that transgene-
mediated release of GABA in the dorsal horn results in a reduction
in pain-related behaviors? One possibility regards the distinct but
overlapping roles played by GABAA and GABAB receptors. While
changes in KCC2 will result in a change the reversal potential of
the GABAAR this change would not be expected to have an effect
on GABABR function. The observations in our current study, indi-
cating that vector-mediated release of GABA results in a reduction
in pain-related behaviors in the rat likely reﬂects presynaptic GA-
BABR effects, since the effect of GABA in preventing the increase in
NaV1.7 in the DRG of diabetic rats is clearly presynaptic, though the
possible additional role of postsynaptic effects cannot be excluded.4.2. NaV1.7 in DRG neurons plays an important role in neuropathic
pain
Neuropathic pain results from hyperexcitability of primary
afferent nociceptors that may result from electrical discharges at
the site of axonal injury or ectopic/spontaneous activity in DRG
neurons (Baron, 2000; Devor, 2006; Sukhotinsky et al., 2004).
M. Chattopadhyay et al. / European Journal of Pain 15 (2011) 913–920 919Voltage-gated sodium channel isoforms expressed in nociceptive
neurons participate in ﬁne tuning the ﬁring properties of nocicep-
tors (Devor, 2006; Lai et al., 2003), and among these isoforms there
is evidence that NaV1.7 in DRG neurons, plays a critical role in the
pathogenesis of neuropathic pain (Black et al., 2004; Cummins
et al., 2007; Ekberg and Adams, 2006; Wilson-Gerwing et al.,
2008). Gain of function mutations in the SCN9A gene coding for
NaV1.7 leads to conditions characterized by spontaneous pain
including primary erythermalgia and paroxysmal extreme pain
disorder (Dib-Hajj et al., 2007; Drenth and Waxman, 2007); loss
of function mutations in SCN9A results in an inherited channelop-
athy characterized by congenital insensitivity to pain (Cox et al.,
2006); and hyperexcitability of primary afferents in human PDN
is associated with increased inter-nodal sodium currents (Misawa
et al., 2009).
In rats with STZ-induced diabetes the amount of NaV1.7 protein
in DRG neurons is increased (Chattopadhyay et al., 2008; Hong
et al., 2004), and alterations in physiologic properties of the DRG
neurons from diabetic rats with PDN concordant with this increase
have been deﬁned (Hong et al., 2004). The embryonic NaV isoform
NaV1.3 is also increased in DRG of diabetic animals (Hong et al.,
2004), but the total amount of NaV1.3 in DRG neurons is very
low, and unlikely to contribute signiﬁcantly to the pain phenotype.
Other isoforms present in DRG neurons, such as NaV1.8, are re-
duced in animals with PDN and unlikely to play an important role
in the pathogenesis of pain in these animals. While ﬁnal proof that
neuropathic pain in diabetic animals results from the increase in
NaV1.7 will require selective knock-down of NaV1.7 or selective
interference with NaV1.7 function, taken together, the evidence
form inherited forms of neuropathic pain and the observations in
animals with PDN strongly implicate increases in NaV1.7 protein
in pathogenesis of neuropathic pain in this condition. The results
presented here do not exclude the possibility that alterations in
the biophysical properties of voltage-gated sodium channels
resulting from phosphorylation or other post-translational modiﬁ-
cations may also play a role in increasing electrical excitability of
peripheral afferents in diabetic animals, but experiments to inves-
tigate these effects are beyond the scope of the current
investigation.
4.3. GABABR activation and NaV protein levels
The observation that GABA prevents the increase in NaV1.7 in
the DRG of diabetic animals provides a second means through
which GABA may be reducing neuropathic pain in these animals.
Considered in conjunction with our previous study showing that
continuous release of the inhibitory neurotransmitter enkephalin
in diabetic animals reduces pain coincident with a reduction in
NaV1.7 levels in DRG neurons through activation of the DOR
(Chattopadhyay et al., 2008), the current results suggests the exis-
tence of a novel common mechanism of presynaptic GPCR regula-
tion of voltage-gated channel protein levels. Bicuculline block of
the GABAA receptor had no effect on vector-mediated GABA release
reduction in NaV1.7 protein in DRG neurons exposed to hypergly-
cemic conditions. While this does not entirely exclude the possibil-
ity of a GABAA receptor-mediated effect that might be observed
using other doses of the inhibitor, taken together the results of
the in vitro experiments clearly support a role for GABA acting
through the GABAB receptor on regulating NaV1.7 levels.
4.4. Implications of the regulation of NaV 1.7 by GPCR
The data in the current report indicate that vector-mediated re-
lease of GABA may provide an analgesic effect in PDN through at
least two distinct mechanisms: actions as an inhibitory neuro-
transmitter as well as distinct effects to reduce the amount ofNaV1.7 in DRG neurons. Whether there are other changes in DRG
phenotype produced by continuous GABAB or GABAA receptor acti-
vation is beyond the scope of the current experiments, but may be
interesting to explore in the future. However, the ﬁndings that re-
veal a previously unrecognized relationship between this presyn-
aptic GPCR and the level of the voltage-gated channel in the
primary sensory neuron have potential implications for the regula-
tion of these channels in normal homeostasis. Taken together with
our previous ﬁndings of a similar relationship between continuous
activation of the DOR GPCR and NaV1.7 levels in DRG neurons, the
results suggest that it is possible that continuous activation of
GPCR in vivo by release of endogenous neurotransmitters may reg-
ulate the steady state levels of voltage gated ion channels, and in
addition provide insight that may be useful in designing therapies
to treat painful diabetic neuropathy.
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